QUEBEC CITY, QUEBEC, Sep 8, 2004 -- Renaud Beauchesne, President and Chief Executive Officer of Advitech (TSX-V: AVI), announced today the appointment of Dr. Georges M. Halpern, MD, PhD, to its Scientific Advisory Board. Advitech is a Canadian biotech company currently involved in developing a new oral treatment for psoriasis for which it has just received positive results without undesirable side effects after 16 weeks of a clinical trial.
"It is an honour and pleasure to welcome Dr Halpern to our group of distinguished scientific advisors," stated Renaud Beauchesne. "Advitech is pursuing the development of novel therapies targeting auto-immune disorders and Dr Halpern's expertise in immunology combined with his outstanding scientific expertise will undoubtedly benefit our company. We will also seek his advice on our current XP-828L program, a growth-factor based oral treatment for psoriasis, as we enter our second clinical study on its safety and efficacy from which we expect to have results by the second quarter of 2005."
Professor Emeritus of Medicine, University of California Davis, Dr. Halpern is currently Distinguished Professor of Pharmaceutical Sciences at the Hong Kong Polytechnic University and Honorary Professor of Pharmacology at the University of Hong Kong. Dr Halpern has worked and lectured in 76 countries. He is recognized worldwide for his many contributions to the field of medicine and is an internationally recognized authority on allergies, asthma, immunology, nutrition, and alternative medicine. Dr. Halpern is also the author of over 150 scientific publications. He resides in Portola Valley, California.
Born a French citizen in Warsaw, Poland, he was raised in Paris, where he attended the Sorbonne. From there he went on to receive his medical degree from the Faculty of Medicine of Paris. He received his PhD DSc degree, with highest honors and jury honors, from the Faculty of Pharmacy, University of Paris-South. Dr. Halpern is a Fellow of the Royal Society of Medicine (London) and of 26 other prestigious national, foreign and international academies and scientific societies. Georges M. Halpern is the author of seventeen books and 56 book chapters and has published 138 original papers and hundreds of reviews and abstracts.
Dr. Halpern has been and continues to be very active as a consultant for governmental, national and international agencies on public health issues and infectious diseases as well as asthma and allergic conditions. He also does consulting for pharmaceutical, diagnostic and nutraceutical companies, as well as for the food, wine, and water industries.
In 1985, he was awarded the Medal of Vermeil by the City of Paris for his outstanding contributions to medicine, dedication to patients, and personal achievements.
Advitech specializes in the development of bioactive products derived from milk proteins. Its key focus areas are in the fields of immunology and inflammatory processes. Its main platform, XP-828L, is a bioactive complex used in the development of an oral treatment for psoriasis and other immune system disorders. Psoriasis affects between 2-3% of the global population and more than 6 million adults in North America alone. Advitech has 15 employees, with more than half of them engaged in research and development activities at its facility at Universite Laval in Quebec City.
Advitech's common shares are listed on the TSX Venture exchange under the symbol AVI. The number of common shares outstanding is 54,723,627.
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward- looking statements.